Strong Year-Over-Year Growth
Sales increased 11% year-over-year on both a reported and organic basis for Q2 2025. Adjusted operating income grew 15%, and adjusted EPS increased by 19% to $1.55.
Cardio & Vascular Segment Performance
Cardio & Vascular sales increased 24% in Q2 2025, driven by new product ramps and strong customer demand in neurovascular. On a trailing 4-quarter basis, C&V sales increased 17% year-over-year.
Increased Outlook for 2025
The company raised the midpoint of its adjusted operating income and EPS outlook, expecting full-year sales growth of 8.5%, adjusted operating income growth of 14%, and adjusted EPS growth of 20%.
Free Cash Flow Improvement
Free cash flow increased by 55% in Q2 2025 to $25 million, driven by operational improvements and lower interest expenses.